Table 1: Summary of characteristics in the studies analyzed.

 

Study

Features

Redwan,

2017

N = 71

Saluja,

2016

N = 55

Saul,

2015

N = 61

Varadarajulu,

2013

N = 40

Johnson,

2009

N = 54

Melman,

2009

N = 83

Design

Retrospective

Randomized clinical trial

Retrospective

Randomized

clinical trial

Retrospective

Retrospective

Follow-up [months]

Endoscopy

Surgery

Not

reported

Not

reported

Not

reported

24

 

0 a 43

1 a 74

Not

reported

Size of pseudocysts

assessed [cm]

Endoscopy, mean

10.3

11.0

6.7

10.5

9.5

9.1

Surgery, mean

10.0

14.2

10.0

11.0

9.1

9.5

Presence of disconnected

PD syndrome

Endoscopy

Not

reported

Not

reported

13

15

Not

reported

Not

reported

Surgery

7

Not reported

Transpapillary

pancreatic stent

2 de 35

Not

reported

Not

reported

10 de 50

Not

reported

Not

reported

Therapeutic success

Endoscopy, n (%)

32 (91.4)

31 (85.0)

19 (90.5)

19 (95.0)

21 (87.5)

38 (84.4)

Surgery, n (%)

36 (100.0)

20 (100.0)

39 (90.7)

20 (100.0)

28 (93.3)

35 (92.1)

p

0.01

0.14

0.74

0.50

0.39

≤ 0.01

OR

0.12

0.17

0.97

0.32

0.5

0.23

Adverse events

Endoscopy, n (%)

3 (8.6)

10 (28.5)

5 (23.8)

0 (0)

3 (12.5)

7 (15.6)

Surgery, n (%)

7 (19.4)

2 (10.0)

11 (25.5)

2 (10.0)

6 (20.0)

5 (22.7)

p

0.08

0.17

0.87

0.24

1.0

≥ 0.05

OR

0.38

0.27

0.91

0.47

0.57

0.63

Recurrence

Endoscopy, n (%)

4 (11.4)

Not

reported

2 (9.5)

0 (0)

Not

reported

Not

reported

Surgery, n (%)

1 (2.78)

2 (4.5)

1 (15.0)

OR

0.3048

N/A

2.16

1

N/A

N/A

In-hospital stay [days]

Endoscopy, mean

3.9

6.4

0

2

Not

reported

Not

reported

Surgery, mean

7.1

5.9

7

6

In-hospital cost [USD]

Endoscopy,

mean ± SD

Not

reported

Not

reported

3,092 ± 1,705

7,011 ± 4,171

Not

reported

Not

reported

Surgery,

mean ± SD

7,734 ± 623

15,052 ± 10,670

p

N/A

N/A

< 0.0001

0.001

N/A

N/A

PD = pancreatic duct.

N/A = not applicable.